ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Latest NewsMORE >>

Pembrolizumab (Keytruda), when studied in 2 clinical trials for the treatment of patients with pretreated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), showed an objective response rate (ORR) of 18%, according to findings presented at the 2016 ASCO Annual Meeting.

Latest JournalAll Journals >>

Targeted Therapies in Oncology October 2015
Targeted Therapies in Oncology
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.